期刊
TUMOR BIOLOGY
卷 36, 期 11, 页码 8425-8437出版社
SAGE PUBLICATIONS LTD
DOI: 10.1007/s13277-015-3575-z
关键词
APL; MST-312; Telomerase; NF-kappa B
类别
资金
- Iran University of Medical Sciences [23232]
Telomerase-targeted therapy for cancer has received great attention because telomerase is expressed in almost all cancer cells but is inactive in most normal somatic cells. This study was aimed to investigate the effects of telomerase inhibitor MST-312, a chemically modified derivative of epigallocatechin gallate (EGCG), on acute promyelocytic leukemia (APL) cells. Our results showed that MST-312 exerted a dose-dependent short-term cytotoxic effect on APL cells, with G2/M cell cycle arrest. Moreover, MST-312 induced apoptosis of APL cells in caspase-mediated manner. Telomeric repeat amplification protocol (TRAP) assay revealed significant reduction in telomerase activity of APL cells following short-term exposure to MST-312. Interestingly, MST-312-induced telomerase inhibition was coupled with suppression of NF-kappa B activity as evidenced by inhibition of I kappa B alpha phosphorylation and its degradation and decreased NF-kappa B DNA binding activity. In addition, gene expression analysis showed downregulation of genes regulated by NF-kappa B, such as antiapoptotic (survivin, Bcl-2, Mcl-1), proliferative (c-Myc), and telomerase-related (hTERT) genes. Importantly, MST-312 did not show any apoptotic effect in normal human peripheral blood mononuclear cells (PBMCs). In conclusion, our data suggest that dual inhibition of telomerase activity and NF-kappa B pathway by MST-312 represents a novel treatment strategy for APL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据